TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36592505
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg zoledronic acid 6-monthly (≤6 infusions, n=170)
Study: 36592505
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg zoledronic acid 6-monthly (≥7 infusions, n=555)
Study: 36592507
Drug: Ipilimumab (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipilimumab (1 mg/kg every 6 weeks for a maximum of two infusions), Nivolumab (6 mg/kg every four weeks), Tocilizumab (8 mg/kg every four weeks), and SBRT (15 Gy on day one of the first cycle)
Study: 36592878
Drug: Zalunfiban dose
Normalized name: Zalunfiban
DrugBank: Zalunfiban (DB18766)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zalunfiban dose 1 (0.110 mg/kg)
Study: 36592878
Drug: Zalunfiban dose
Normalized name: Zalunfiban
DrugBank: Zalunfiban (DB18766)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zalunfiban dose 2 (0.130 mg/kg)
Study: 36592878
Drug: Zalunfiban (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zalunfiban (both doses)
Study: 36593652
Drug: Live attenuated
Normalized name: mumps, live attenuated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live attenuated varicella vaccine (VarV) and inactivated hepatitis A vaccine (HepA) co-administered (Group A)
Study: 36593652
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (Group B) - VarV and HepA administered separately
Study: 36593702
Drug: Weekly umbilical
Normalized name: Bos taurus umbilical cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly umbilical artery Doppler ultrasound
Study: 36593702
Drug: Bi-weekly umbilical
Normalized name: selinexor
DrugBank: Selinexor (DB11942)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Bi-weekly umbilical artery Doppler ultrasound
Study: 36593729
Drug: Corticosteroid tapering
Normalized name: mitapivat
DrugBank: Mitapivat (DB16236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Corticosteroid tapering in patients receiving subcutaneous daratumumab
Study: 36594077
Drug: 5 mm-bolus
Normalized name: Peumus boldus leaf
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mm-bolus daily (HR group)
Study: 36594167
Drug: Polatuzumab vedotin
Normalized name: polatuzumab vedotin
DrugBank: Polatuzumab vedotin (DB12240)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Polatuzumab vedotin in combination with venetoclax and an anti-CD20 antibody
Study: 36594428
Drug: Low protein
Normalized name: Low protein mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low protein diet (LPD) (0.6 to 0.8 g/kg/day)
Study: 36594428
Drug: Usual or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual or unrestricted protein diet (UPD) (≥ 1.0 g/kg/day)
Study: 36594748
Drug: Laparoscopy-assisted TME
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laparoscopy-assisted TME (L-TME)
Study: 36594947
Drug: Remifentanil (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil (3 to 4 μg/kg); n=575
Study: 36594947
Drug: Neuromuscular blockers
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neuromuscular blockers (1 mg/kg of succinylcholine or rocuronium); n=575
Study: 36594947
Drug: Remifentanil (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil (3 to 4 μg/kg); n=565 (per-protocol population)
Study: 36594947
Drug: Neuromuscular blockers
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neuromuscular blockers (1 mg/kg of succinylcholine or rocuronium); n=565 (per-protocol population)
Study: 36594987
Drug: Severity score
Normalized name: fecal microbiota spores, live Oral Capsule [Vowst]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Severity score 2 (no oxygen therapy)
Study: 36595569
Drug: Atezolizumab with
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Atezolizumab with standard chemotherapy and bevacizumab
Study: 36595569
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with standard chemotherapy and bevacizumab
Study: 36596439
Drug: Self-administered, multidimensional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-administered, multidimensional bladder health scales and function indices (paper and electronic forms)
Study: 36596609
Drug: Dexamethasone preparations
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone preparations
Study: 36596632
Drug: Monthly virtual
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly virtual MS symptom education groups (six sessions)
Study: 36596682
Drug: Appropriate empirical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Appropriate empirical antibiotics
Study: 36596682
Drug: Inappropriate empirical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inappropriate empirical antibiotics
Study: 36596787
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of immune checkpoint inhibitor (camrelizumab), antiangiogenesis (apatinib), and chemotherapy (S-1 ± oxaliplatin)
Study: 36596867
Drug: Symptomatic intracranial
Normalized name: ALCOHOL 80 mL in 100 mL INTRACRANIAL LIQUID [80% Alcohol Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symptomatic intracranial hemorrhage (sICH) after anticoagulants
Study: 36596867
Drug: Intracranial hemorrhage
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracranial hemorrhage (ICH) after anticoagulants
Study: 36596867
Drug: Systemic hemorrhage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic hemorrhage after anticoagulants
Study: 36596945
Drug: Oropharyngeal therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oropharyngeal therapy with mother's own milk (OPT-MOM)
Study: 36597076
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg ferroquine plus artefenomel 300 mg
Study: 36597076
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg ferroquine plus artefenomel 600 mg
Study: 36597076
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg ferroquine plus artefenomel 1000 mg
Study: 36597076
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg ferroquine
Study: 36597103
Drug: Glucocorticoid injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucocorticoid injection into the infrapatellar fat pad (IPFP)
Study: 36597103
Drug: Saline injection
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline injection into the infrapatellar fat pad (IPFP)
Study: 36597115
Drug: 4-dose azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 4-dose azithromycin (AZI)
Study: 36597115
Drug: 2-dose azithromycin
Normalized name: azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2-dose azithromycin (AZI)
Study: 36597163
Drug: Intranasal dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal dexmedetomidine 2 μg/kg and ketamine 3 mg/kg
Study: 36597543
Drug: Metformin (1,500mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (1,500mg per day for 14 days)
Study: 36597543
Drug: Fluvoxamine (50mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvoxamine (50mg on day one then 50mg twice daily through 14 days)
Study: 36598621
Drug: SCTV01E vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCTV01E vaccine
Study: 36598621
Drug: D614G monovalent
Normalized name: rotavirus, monovalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: D614G monovalent vaccine
Study: 36598770
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (TAU) with clinician education alone.
Study: 36599114
Drug: Daratumumab in
Normalized name: daratumumab Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daratumumab in combination with lenalidomide and dexamethasone (D-Rd)
Study: 36599120
Drug: MR-IGABT with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: MR-IGABT with external beam radiotherapy and concurrent chemotherapy
Study: 36599321
Drug: 20 g
Normalized name: PEG-20 glyceryl oleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 g of Mg
Study: 36599321
Drug: Lower serum
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower serum Mg level (<1.7 mg/dL) posttreatment
Study: 36599321
Drug: Normal serum
Normalized name: Albumin, Normal Serum, Human
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal serum Mg level (≥1.7 mg/dL) posttreatment
Study: 36599549
Drug: Sacubitril/Valsartan (Sac/Val)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sacubitril/Valsartan (Sac/Val) therapy
Study: 36599736
Drug: HEV 239
Normalized name: Immunoglobulin G1-lambda2, anti-[Homo sapiens IL33 (interleukin 33, DVS27, NF-HEV, IL1F11)], monoclonal antibody; gamma1 heavy chain (1-456) [VH (Homo sapiens IGHV3-23*01 (93.9%) -(IGHD) -IGHJ4*01 (85.7%) L123>M (121)) CDR-IMGT [8.8.19] (26-33.51-58.97-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: HEV 239 vaccine (two doses at 0 and 1 month)
Study: 36599736
Drug: Control (Hepatitis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (Hepatitis B virus vaccine)
Study: 36600247
Drug: HL-085 (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: HL-085 (12 mg twice daily)
Study: 36600247
Drug: HL-085 (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: HL-085 (up to 18 mg twice daily)
Study: 36600247
Drug: HL-085 (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: HL-085 (all doses)
Study: 36600353
Drug: Free treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Free treatment (artemisinin combination therapies (ACTs)) for positive malaria tests
Study: 36600374
Drug: Methotrexate 10
Normalized name: methotrexate 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate 10 mg once a week
Study: 36600424
Drug: Active immunotherapy
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active immunotherapy with anakinra (recombinant interleukin-1 receptor antagonist) intravenously for patients with MALS
Study: 36600424
Drug: Active immunotherapy
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active immunotherapy with subcutaneous recombinant human interferon-gamma for patients with immunoparalysis
Study: 36600427
Drug: HCL-LCD (Hybrid
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCL-LCD (Hybrid Closed Loop system with Low Carbohydrate Diet, <130 g carbohydrate/day) for >8 months
Study: 36600534
Drug: Adjuvant radiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant radiotherapy with concurrent and adjuvant durvalumab for 1 year
Study: 36600535
Drug: Acupuncture with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture with additional manual-movement and mind-body therapies (group B)
Study: 36600561
Drug: Mupadolimab (anti-CD73
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mupadolimab (anti-CD73 antibody)
Study: 36600670
Drug: Ponatinib 45
Normalized name: PONATinib 45 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ponatinib 45 mg daily for 14 days during induction, then 45 mg daily continuously or 30 mg daily continuously with dose reduction to 15 mg daily upon achieving complete molecular response (CMR). Maintenance therapy included daily ponatinib and vincristine-prednisone monthly for 2 years, followed by daily ponatinib indefinitely. Intrathecal injections of cytarabine and methotrexate for CNS prophylaxis.
Study: 36600670
Drug: Adverse events
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adverse events related to ponatinib and hyper-CVAD treatment.
Study: 36601119
Drug: Lymphodepletion with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lymphodepletion with fludarabine and cyclophosphamide prior to CAR-T infusion
Study: 36601119
Drug: CLIC-1901 dose
Normalized name: somatropin
DrugBank: Somatotropin (DB00052)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CLIC-1901 dose infused
Study: 36601286
Drug: Young Person's
Approvals — FDA: no, EMA: no, PMDA: no
Description: Young Person's Face IT (YPF), an online intervention based on cognitive behavioural therapy and social skills training.
Study: 36601956
Drug: Sacubitril/valsartan administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sacubitril/valsartan administered twice daily for 52 weeks
Study: 36601956
Drug: Enalapril administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril administered twice daily for 52 weeks
Study: 38608693
Drug: Cabozantinib 60
Normalized name: cabozantinib 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabozantinib 60 mg/day
Study: 36602226
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of pyrotinib, letrozole, and dalpiciclib
Study: 36602718
Drug: Topical DEX
Normalized name: Stri-Dex Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical DEX (dexamethasone)
Study: 36602718
Drug: Topical DICLO
Normalized name: Xiclo Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical DICLO (diclofenac)
Study: 36602718
Drug: Topical DEX
Normalized name: Stri-Dex Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical DEX + DICLO (dexamethasone and diclofenac)
Study: 36602718
Drug: Topical DEX
Normalized name: Stri-Dex Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical DEX
Study: 36602718
Drug: Topical DICLO
Normalized name: Xiclo Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical DICLO
Study: 36602718
Drug: Topical DEX
Normalized name: Stri-Dex Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical DEX + DICLO
Study: 36602796
Drug: gemcitabine (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: gemcitabine (1000 mg/m2) and nab-paclitaxel (125 mg/m2)
Study: 36602796
Drug: gemcitabine (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: gemcitabine (1000 mg/m2) and nab-paclitaxel (125 mg/m2) and NPC-1C (1.5 mg/kg every 2 weeks)
Study: 36602914
Drug: Mindfulness, safety,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness, safety, and health program (self-administered, 30-minute sessions once a week for 12 weeks, using web-based learning modules and the Headspace app)
Study: 36602927
Drug: Second-generation atypical
Normalized name: regenerated cellulose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second-generation atypical antipsychotics
Study: 36603175
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy with gemcitabine and split-dose cisplatin (GC)
Study: 36604127
Drug: Nab-paclitaxel and
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nab-paclitaxel and cisplatin administered via pressurised intraperitoneal aerosol chemotherapy (PIPAC)
Study: 36604262
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D 60,000 IU monthly
Study: 36604756
Drug: Intravitreal sirolimus
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravitreal sirolimus and adjunct aflibercept (combination)
Study: 36604756
Drug: Aflibercept monotherapy
Normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Aflibercept monotherapy (control)
Study: 36605436
Drug: Avelumab (PD-L1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avelumab (PD-L1 antibody) combined with FOLFOX chemotherapy and cetuximab (anti-EGFR antibody)
Study: 36606100
Drug: DAA regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: DAA regimen (direct-acting antiviral treatment); 8 patients started treatment
Study: 36606536
Drug: Secukinumab 300
Normalized name: secukinumab 300 MG in 2 ML Auto-Injector
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secukinumab 300 mg administered subcutaneously for 52 weeks
Study: 36607429
Drug: Zolbetuximab +
Normalized name: Zolbetuximab
DrugBank: Zolbetuximab (DB15118)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolbetuximab + Zoledronic Acid (ZA) + Intermediate-dose IL-2 (3 mIU) (n=7)
Study: 36607429
Drug: Zolbetuximab +
Normalized name: Zolbetuximab
DrugBank: Zolbetuximab (DB15118)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolbetuximab + Zoledronic Acid (ZA) + Low-dose IL-2 (1 mIU) (n=9)
Study: 36607429
Drug: Zolbetuximab +
Normalized name: Zolbetuximab
DrugBank: Zolbetuximab (DB15118)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolbetuximab + Zoledronic Acid (ZA) + IL-2 (both doses)
Study: 36607735
Drug: PVX2 vaccination
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PVX2 vaccination (twice with HPV16-targeting pNGVL4a-Sig/E7(detox)/HSP70 plasmid and once with TA-CIN protein)
Study: 36608310
Drug: ibrutinib 420
Normalized name: ibrutinib 420 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ibrutinib 420 mg once daily plus prednisone (1 mg/kg once daily)
Study: 36608310
Drug: ibrutinib treatment
Normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: ibrutinib treatment
Study: 36608320
Drug: Encorafenib 450
Approvals — FDA: no, EMA: no, PMDA: no
Description: Encorafenib 450 mg once daily and binimetinib 45 mg twice daily
Study: 36608383
Drug: Interval cytoreductive
Normalized name: Minerval
DrugBank: Idroxioleic acid (DB18213)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interval cytoreductive surgery (ICS) followed by hyperthermic intraperitoneal chemotherapy (HIPEC)
Study: 36608413
Drug: Sucrose (24%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucrose (24% solution)
Study: 36609038
Drug: DCB-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: DCB-based treatment
Study: 36609038
Drug: DES-only treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: DES-only treatment
Study: 36609046
Drug: Transdermal Glyceryl
Normalized name: glyceryl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal Glyceryl Trinitrate Patches
Study: 36609279
Drug: Intermittent Preventive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent Preventive Treatment of malaria in schoolchildren (IPTsc) using dihydroartemisinin-piperaquine (DP) given three times a year in four-month intervals.
Study: 36609978
Drug: rs7975232 CC
Approvals — FDA: no, EMA: no, PMDA: no
Description: rs7975232 CC genotype
Study: 36610464
Drug: Icatibant (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Icatibant (30 mg doses/d for 3 consecutive days plus standard care)
Study: 36610891
Drug: Sunitinib (monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib (monotherapy or combined with local treatment)
Study: 36611210
Drug: Liberal transfusion
Normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liberal transfusion strategy (maintaining hemoglobin concentrations greater than 9 g/dL)
Study: 36611210
Drug: Restrictive transfusion
Normalized name: Pinus spp. wood destructive distillate
DrugBank: Pine tar (DB15840)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restrictive transfusion strategy (maintaining hemoglobin concentrations greater than 7 g/dL)
Study: 36612650
Drug: Monthly telephonic
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly telephonic interventions based on motivational interviewing and collaborative care strategies
Study: 36614923
Drug: oral preventive
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral preventive drugs
Study: 36614923
Drug: oral preventive
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral preventive drugs and onabotulinumtoxinA
Study: 36615174
Drug: Aronia supplementation
Normalized name: Aronia melanocarpa fruit juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aronia supplementation (150 mg anthocyanins daily)
Study: 36617389
Drug: Fixed dose
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed dose of insulin for a fixed range of carbohydrates (FD group)
Study: 36617389
Drug: Precise dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Precise dose of insulin for a precise number of carbohydrates using an insulin-to-carbohydrate ratio (ICR group)
Study: 36617554
Drug: GD2-specific 4SCAR-T
Normalized name: Viral Specific T-lymphocytes
DrugBank: Virus Specific T-Cell (DB15735)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GD2-specific 4SCAR-T cells (infused through intravenous administration alone or combined with intracavitary administration)
Study: 36617560
Drug: Rezivertinib (BPI-7711)
Normalized name: Abivertinib
DrugBank: Abivertinib (DB15327)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rezivertinib (BPI-7711) 180 mg orally once daily
Study: 36617848
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment for midportion Achilles tendinopathy
Study: 36618582
Drug: 18 G
Normalized name: flotufolastat F 18 gallium
Approvals — FDA: no, EMA: no, PMDA: no
Description: 18 G Tuohy needle
Study: 36618582
Drug: 25 G
Normalized name: AndroGel 1.25 g Packets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 G Tuohy needle
Study: 36618900
Drug: Ibrutinib 560
Normalized name: ibrutinib 560 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibrutinib 560 mg once daily, Lenalidomide 20 mg or 25 mg once daily on Days 1-21 of each 28-day cycle, Rituximab 375 mg/m2
Study: 36619332
Drug: Daily intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily intake of 57 g Jarlsberg cheese (J-group)
Study: 36619332
Drug: Daily intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily intake of 25-50 g Camembert (C-group)
Study: 36619332
Drug: Daily intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily intake of 57 g Jarlsberg cheese (after switching from C-group)
Study: 36619630
Drug: High-dose norepinephrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose norepinephrine (≥0.3 μg/kg/min)
Study: 36619630
Drug: Norepinephrine (≥0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norepinephrine (≥0.1 μg/kg/min)
Study: 36620632
Drug: Intravenous antibacterial
Normalized name: Dermoplast Antibacterial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous antibacterial prophylaxis (IV ABX) with compliance rates of 96.6% and biologic envelope hydrated in antibiotics (77.1%)
Study: 36620632
Drug: Biologic envelope
Normalized name: Zaire ebolavirus envelope glycoprotein Injection [Ervebo]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biologic envelope hydrated in antibiotics